Pacific Biosciences of California (PACB) vs. Cytosorbents (CTSO) Critical Review

Pacific Biosciences of California (NASDAQ: PACB) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Valuation & Earnings

This table compares Pacific Biosciences of California and Cytosorbents’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pacific Biosciences of California $93.47 million 3.16 -$92.19 million ($0.89) -2.85
Cytosorbents $9.53 million 21.98 -$11.93 million ($0.38) -19.21

Cytosorbents has lower revenue, but higher earnings than Pacific Biosciences of California. Cytosorbents is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pacific Biosciences of California and Cytosorbents’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pacific Biosciences of California -98.63% -96.55% -58.68%
Cytosorbents -67.83% -233.72% -57.58%

Analyst Ratings

This is a breakdown of current ratings and price targets for Pacific Biosciences of California and Cytosorbents, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacific Biosciences of California 0 2 1 0 2.33
Cytosorbents 0 0 5 0 3.00

Pacific Biosciences of California presently has a consensus target price of $6.27, suggesting a potential upside of 146.72%. Cytosorbents has a consensus target price of $10.65, suggesting a potential upside of 45.89%. Given Pacific Biosciences of California’s higher possible upside, analysts plainly believe Pacific Biosciences of California is more favorable than Cytosorbents.

Insider and Institutional Ownership

70.9% of Pacific Biosciences of California shares are held by institutional investors. Comparatively, 9.5% of Cytosorbents shares are held by institutional investors. 17.8% of Pacific Biosciences of California shares are held by insiders. Comparatively, 5.6% of Cytosorbents shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Pacific Biosciences of California has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.

Cytosorbents Company Profile

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply